Skip to main content
. 2017 Feb 21;18:14. doi: 10.1186/s40360-017-0118-9

Table 2.

Viability of SP- and Non-SP cells treated with gefitinib and Kv channels blocker or Kv7 opener

Cell viability (%) Gefitinib (2 μM) TEA (5 mM) 4-AP (2 mM) Flupirtine (30 μM) TEA (5 mM) 4-AP (2 mM) Flupirtine (30 μM)
(Gef 2 μM)
Non-SP 59.68 (±4.54) 79.09 (±5.62) 72.46 (±5.45) 58.08 (±5.67) 20.39 (±3.27) 20.54 (±5.22) 32.02 (±3.48)
SP 105.32 (±10.92) 84.22 (±4.40) 83.32 (±5.43) 63.00 (±8.81) 23.84 (±4.27) 27.44 (±8.87) 30.63 (±3.95)